Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou Connect Biopharma Closes Early Fundings for $25 Million

publication date: Jan 25, 2017
Suzhou Connect Biopharma raised a total of $25 million in two tranches: $20 million in a Series A round led by Qiming, and slightly earlier, $5 million in a pre-A financing. Founded in 2012, Connect is developing several G-protein coupled receptor antagonists to treat autoimmune diseases and cancer. Its lead molecule, CBP-307, has completed a Phase I trial in Australia as a treatment for inflammatory bowel disease (IBD). Connect discovers its own candidates and also in-licenses other projects. It conducts early development in-house and uses CROs for later work. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital